ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Vir To Investigate RNAi, Ant
Generics BulletinCelltrion Inc. and Pfizer Inc. ’s Inflectra (infliximab-dyyb) does not infringe Janssen Biotech Inc. ’s cell culture media patent, a federal judge ruled July 30, rejecting the last of the Remica
Pink SheetCelltrion Inc. and Pfizer Inc. ’s Inflectra (infliximab-dyyb) does not infringe Janssen Biotech Inc. ’s cell culture media patent, a federal judge ruled July 30, rejecting the last of the Remica
In VivoDevice Transactions Financing by device companies in the third quarter of 2017 totaled $2.38 billion, double Q2's $1.2 billion. ( See Exhibit 1. ) Debt again this quarter made up most of the aggregate